Urinary Tract Infection

8
Pipeline Programs
6
Companies
6
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 5 programs with unclassified modality

On Market (3)

Approved therapies currently available

U
ERTAPENEM SODIUMApproved
ertapenem sodium
Unknown Company
intramuscular, intravenous2018
M&
INVANZApproved
ertapenem sodium
Merck & Co.
intramuscular, intravenous2001
U
LEVOFLOXACINApproved
levofloxacin
Unknown Company
Fluoroquinolone Antibacterial [EPC]oral2012

Competitive Landscape

6 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
1
ertapenem sodiumPhase 31 trial
Active Trials
NCT00379951Completed107Est. May 2006
Astellas
AstellasChina - Shenyang
1 program
1
LevofloxacinPhase 4Small Molecule1 trial
Active Trials
NCT02094703Unknown126Est. Dec 2014
Pfizer
PfizerNEW YORK, NY
1 program
1
Zavicefta, Ceftazidime-AvibactamPhase 41 trial
Active Trials
NCT04882085Completed60Est. Aug 2023
Takeda
TakedaTOKYO, Japan
1 program
1
FlomoxefPhase 31 trial
Active Trials
NCT02302092Terminated13Est. Dec 2016
DynamiCure
DynamiCureMA - Waltham
1 program
1
Fosfomycun-trometamolPhase 31 trial
Active Trials
NCT06822751Not Yet RecruitingEst. Jun 2029
C
ColoplastAustralia - Mulgrave
1 program
E. coli 83972N/A1 trial
Active Trials
NCT00927316CompletedEst. Dec 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
PfizerZavicefta, Ceftazidime-Avibactam
AstellasLevofloxacin
DynamiCureFosfomycun-trometamol
TakedaFlomoxef
Merck & Co.ertapenem sodium
ColoplastE. coli 83972

Clinical Trials (6)

Total enrollment: 306 patients across 6 trials

NCT04882085PfizerZavicefta, Ceftazidime-Avibactam

Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

Start: Aug 2021Est. completion: Aug 202360 patients
Phase 4Completed
NCT02094703AstellasLevofloxacin

The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females

Start: Apr 2013Est. completion: Dec 2014126 patients
Phase 4Unknown
NCT06822751DynamiCureFosfomycun-trometamol

FOsfomycin for Male Urinary Tract Infection

Start: Mar 2026Est. completion: Jun 2029
Phase 3Not Yet Recruiting
NCT02302092TakedaFlomoxef

An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections

Start: Dec 2015Est. completion: Dec 201613 patients
Phase 3Terminated
NCT00379951Merck & Co.ertapenem sodium

A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)

Start: Jun 2005Est. completion: May 2006107 patients
Phase 3Completed
NCT00927316ColoplastE. coli 83972

E. Coli 83972 Induced Asymptomatic Bacteriuria (ABU) in Patients With Recurrent Urinary Tract Infections (UTI)

Start: Mar 2003Est. completion: Dec 2006
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space